Mary Elizabeth Strek to Pyridones
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Pyridones.
Connection Strength
2.072
-
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
Score: 0.924
-
Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest. 2016 Dec; 150(6):1371-1386.
Score: 0.536
-
Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020 10; 158(4):1526-1534.
Score: 0.174
-
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019 Sep 06; 20(1):205.
Score: 0.166
-
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018 Dec 31; 27(150).
Score: 0.158
-
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
Score: 0.115